Pharmacological interventions in corticobasal degeneration: a review

Caixeta, Leonardo; Caixeta, Victor de Melo; Nogueira, Yanley Lucio; Aversi-Ferreira, Tales Alexandre

doi:10.1590/1980-57642020dn14-030006

Cited by 3 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinically, the diagnosis of CBD is now referred to CBS, which can be a manifestation of pathologies beyond CBD, as it overlaps with several forms of dementia of differing neuropathologies (Armstrong et al, 2013). As a result of its diverse clinical manifestations and a lack of biomarkers enabling early diagnosis, it is estimated that only 25-56% of patients are diagnosed correctly with CBS before death (Lee et al, 2011;Alster et al, 2018Alster et al, , 2020Svenningsson, 2019;Caixeta et al, 2020).…”

Section: Corticobasal Degenerationmentioning

confidence: 99%

“…These trials include Fasudil (ROCK-inhibitor) (US National Library of Medicine, 2021), TPI-287 (microtubule-stabilizing molecule) (US National Library of Medicine, 2014Medicine, -2020Tsai et al, 2020), and gosuranemab (anti-tau antibody) (US National Library of Medicine, 2018Medicine, -2019, mentioned in the PSP section. Current CBD treatment is primarily based on relieving its symptoms by pharmacotherapy (Caixeta et al, 2020). Potential novel therapeutic approaches for PSP and CBS are summarized in Table 1.…”

Section: Corticobasal Degenerationmentioning

confidence: 99%

See 1 more Smart Citation

Novel Therapies for Parkinsonian Syndromes–Recent Progress and Future Perspectives

Przewodowska

Marzec

Madetko

2021

Front. Mol. Neurosci.

View full text Add to dashboard Cite

Background: Atypical parkinsonian syndromes are rare, fatal neurodegenerative diseases associated with abnormal protein accumulation in the brain. Examples of these syndromes include progressive supranuclear palsy, multiple system atrophy, and corticobasal degeneration. A common clinical feature in parkinsonism is a limited improvement with levodopa. So far, there are no disease-modifying treatments to address these conditions, and therapy is only limited to the alleviation of symptoms. Diagnosis is devastating for patients, as prognosis is extremely poor, and the disease tends to progress rapidly. Currently, potential causes and neuropathological mechanisms involved in these diseases are being widely investigated.Objectives: The goal of this review is to summarize recent advances and gather emerging disease-modifying therapies that could slow the progression of atypical parkinsonian syndromes.Methods: PubMed and Google Scholar databases were searched regarding novel perspectives for atypical parkinsonism treatment. The following medical subject headings were used: “atypical parkinsonian syndromes—therapy,” “treatment of atypical parkinsonian syndromes,” “atypical parkinsonian syndromes—clinical trial,” “therapy of tauopathy,” “alpha-synucleinopathy treatment,” “PSP therapy/treatment,” “CBD therapy/treatment,” “MSA therapy/treatment,” and “atypical parkinsonian syndromes—disease modifying.” All search results were manually reviewed prior to inclusion in this review.Results: Neuroinflammation, mitochondrial dysfunction, microglia activation, proteasomal impairment, and oxidative stress play a role in the neurodegenerative process. Ongoing studies and clinical trials target these components in order to suppress toxic protein accumulation. Various approaches such as stem cell therapy, anti-aggregation/anti-phosphorylation agent administration, or usage of active and passive immunization appear to have promising results.Conclusion: Presently, disease-modifying strategies for atypical parkinsonian syndromes are being actively explored, with encouraging preliminary results. This leads to an assumption that developing accurate, safe, and progression-halting treatment is not far off. Nevertheless, the further investigation remains necessary.

show abstract

Section: Corticobasal Degenerationmentioning

confidence: 99%

Section: Corticobasal Degenerationmentioning

confidence: 99%

Novel Therapies for Parkinsonian Syndromes–Recent Progress and Future Perspectives

Przewodowska

Marzec

Madetko

2021

Front. Mol. Neurosci.

View full text Add to dashboard Cite

show abstract

“…Corticobasal degeneration (CBD) is an extremely rare and sporadic neurodegenerative disease [ 100 ]. The average age of onset is 40 to 70, with an average survival rate of seven years and a yearly incident rate of 0.02 per 100,000 individuals [ 101 ].…”

Section: Atypical Parkinsonism-related Neurodegenerative Disordersmentioning

confidence: 99%

The Genetic Landscape of Parkinsonism-Related Dystonias and Atypical Parkinsonism-Related Syndromes

Díez-Fairén

Jerez

Berghausen

et al. 2021

IJMS

View full text Add to dashboard Cite

In recent decades, genetic research has nominated promising pathways and biological insights contributing to the etiological landscape of parkinsonism-related dystonias and atypical parkinsonism-related syndromes. Several disease-causing mutations and genetic risk factors have been unraveled, providing a deeper molecular understanding of the complex genetic architecture underlying these conditions. These disorders are difficult to accurately diagnose and categorize, thus making genetics research challenging. On one hand, dystonia is an umbrella term linked to clinically heterogeneous forms of disease including dopa-responsive dystonia, myoclonus-dystonia, rapid-onset dystonia-parkinsonism and dystonia-parkinsonism, often viewed as a precursor to Parkinson’s disease. On the other hand, atypical parkinsonism disorders, such as progressive supranuclear palsy, multiple system atrophy and corticobasal degeneration, are rare in nature and represent a wide range of diverse and overlapping phenotypic variabilities, with genetic research limited by sample size availability. The current review summarizes the plethora of available genetic information for these diseases, outlining limits and future directions.

show abstract